At last, the results of Gynecological Oncology Group (GOG) trial 99, a randomized trial comparing postoperative pelvic radiotherapy (RT) to no additional treatment (NAT) in intermediate-risk endometrial carcinoma, are published by Keys et al. in this issue of Gynecologic Oncology.

2019年4月17日 · The high-intermediate–risk criteria as defined in GOG-99 do seem to constitute a high-risk group of patients with recurrence rates of 15% to 20%, even with adjuvant treatment. By including high-risk histologies (serous and clear cell) and cervical involvement (stage II), our study included patients with a higher risk profile than those in the ...

Methods: Four hundred forty-eight consenting patients with "intermediate risk" endometrial adenocarcinoma were randomized after surgery to either no additional therapy (NAT) or whole pelvic radiation therapy (RT). They were followed to determine toxicity, date and location of recurrence, and overall survival.

The purpose of this study is to validate the Gynecologic Oncology Group (GOG) criteria for adjuvant treatment in a different cohort of patients and to evaluate the simplified risk criteria predicting the prognosis and tailoring adjuvant treatment in patients with surgically staged endometrial cancer.

2019年6月12日 · In a randomized trial conducted by the Gynecologic Oncology Group (GOG), GOG 122, chemotherapy was found to be superior to radiotherapy in treating locally advanced disease, and it thus became...

GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma? GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma? Gynecol Oncol. 2004 Mar;92(3):740-3. doi: 10.1016/j.ygyno.2004.01.009. Author Carien L Creutzberg ...

2007年1月23日 · In GOG-99 a high intermediate risk subgroup of patients were defined after randomisation as those with (i) grade 2 and 3, presence of lymphovascular invasion (LVC), and stage 1c; (ii) age 50 or greater with any two risk factors listed above; and (iii) age of at least 70 with any risk factor listed above.

(PORTEC)-1,2 and Gynecologic Oncology Group (GOG)-99 defined high-intermediate risk (HIR) group of surgically staged endometrial cancer patients and demonstrated decreasing recurrence rates following adjuvant radiotherapy (RT) in these population without altering overall survival (OS) [1-3]. In the

2004年5月9日 · The goal of this study (GOG 99) was to investigate the utility of PORT in stage IB, IC and II (occult) patients having undergone complete surgical staging. Materials and Methods. Eligible patients were the "intermediate risk" group from GOG 33, i.e. those presumed to have a 5 year LRR of 20-25%.

2010年5月20日 · Background: GOG 99 defined a subgroup of patients with early stage endometrial cancer with high-intermediate-risk (H-IR) factors that were at recurrence risk of 27%. Criteria included grade 2-3, LVSI, and outer third myometrial invasion.